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Summary
Objective: To examine the potential for rejuvenation of aged periosteum by local injection of transforming growth factor-beta1 (TGF-b1) and
insulin-like growth factor-1 (IGF-1) alone or in combination to induce cambium cell proliferation and enhance in vitro periosteal cartilage
formation.
Methods: A total of 367 New Zealand white rabbits (6, 12, and 24þ month-old) received subperiosteal injections of TGF-b1 and/or IGF-1 per-
cutaneously. After 1, 3, 5, or 7 days, the rabbits were sacriﬁced and cambium cellularity or in vitro cartilage forming capacity was determined.
Results: A signiﬁcant increase in cambium cellularity and thickness, and in vitro cartilage formation was observed after injection of TGF-b1
alone or in combination with IGF-1. In 12 month-old rabbits, mean cambium cellularity increased 5-fold from 49 to 237 cells/mm and in vitro
cartilage production increased 12-fold from 0.8 to 9.7 mg 7 days after TGF-b1 (200 ng) injection compared to vehicle controls (P< 0.0001). A
correlation was observed between cambium cellularity and in vitro cartilage production (R2¼ 0.98). An added beneﬁt of IGF-1 plus TGF-b1 on
in vitro cartilage production compared to TGF-b1 alone was observed in the 2 year-old rabbits. IGF-1 alone generally had no effect on either
cambium cellularity or in vitro cartilage production in any of the age groups.
Conclusions: These results clearly demonstrate that it is possible to increase cambium cellularity and in vitro cartilage production in aged
rabbit periosteum, to levels comparable to younger rabbits, using local injection of TGF-b1 alone or in combination with IGF-1, thereby
rejuvenating aged periosteum.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Periosteum, the connective tissue that surrounds bones,
can be used for tissue engineering or regeneration of
bone and cartilage1e12. However, the principal limitation to
the use of periosteum is the age-related decrease in cam-
bium cellularity and thickness of the cambium where the
precursor cells reside13,14. This decline in precursor cells,
and cambium thinning is consistent with the observed de-
crease in the capacity of aged periosteum to form bone
and cartilage5,13. Previously, we documented that cambium
cellularity and thickness were signiﬁcantly lower in 6, 12
and 24 month-old rabbits compared to 2 month-old rab-
bits13. Likewise, the in vitro cartilage forming capacity was
also reduced by 50% in 6 month-old rabbits and reached
steady state minimal levels by 12 months of age compared
to 1.5e2 month-old rabbits13. Therefore, similar to observa-
tions in humans5, a marked decrease in the biological activ-
ity of rabbit periosteum occurs after completion of skeletal
growth (approximately 6 months of age)1,13. Thus, the rabbit
is an excellent model to study the effect of age on*Address correspondence and reprint requests to: Gregory G.
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723periosteum and potential approaches to rejuvenate aged
periosteum.
Previously, we demonstrated that in vitro periosteal chon-
drogenesis could be induced with a brief exposure (30 to
60 min) of high-dose (50 or 100 ng/mL) transforming growth
factor-beta1 (TGF-b1)15. In addition, we observed that the
combination of insulin-like growth factor-1 (IGF-1) and
TGF-b1 resulted in a signiﬁcant increase in in vitro cartilage
yield as early as 2 weeks compared to either growth factor
alone16. Importantly, the combined treatment also stimulated
signiﬁcantly more proliferation of cambium layer cells during
the ﬁrst week of culture compared to either growth factor
alone. These results suggest that the combined treatment
may be advantageous for rapid stimulation of periosteum.
Joyce et al. demonstrated that periosteum can be stimu-
lated to grow and differentiate into cartilage and bone in situ
after subperiosteal injection of TGF-b in newborn rats17.
Similar results were also reported in rabbits18. In these stud-
ies, stimulation of cambium layer cell proliferation by sub-
periosteal injection of TGF-b2 was observed in rabbits 3
days, 3 months and 2-years old18. However, a quantitative
analysis of the effects of a single subperiosteal injection of
TGF-b or IGF-1 on cambium cellularity and thickness, and
in vitro cartilage formation has not been previously reported.
In this study, we examined the potential for rejuvenation of
aged periosteum by a single local injection of TGF-b1 and
IGF-1 alone or in combination to induce cambium cell
Fig. 1. Flow diagram illustrating the distribution of rabbits and periosteal tissue samples used in this study. A total of 367 New Zealand white
rabbits (6, 12, and 24þ month-old) received subperiosteal injections of growth factors or vehicle in the medial side of the proximal tibia. After 1,
3, 5, or 7 days, the rabbits were sacriﬁced and periosteum containing the injection sites (eight samples per rabbit) was harvested together with
the underlying bone as an intact osteoperiosteal specimen for histology (to determine cambium cellularity and thickness)13, or periosteal
explants were elevated from the bone at the injection sites and cultured for 6 weeks (to determine in vitro cartilage forming capacity)6.
724 G. G. Reinholz et al.: Rejuvenation of Periosteumproliferation and enhance in vitro periosteal cartilage formation
in rabbits. This study was also designed to determine the opti-
mal duration between injection and periosteal graft harvest,
and growth factor concentration and composition for in vivo
cartilage repair studies in this model of aged periosteum.Methods and materialsSTUDY DESIGNAll procedures were conducted with the approval of our Institutional
Animal Care and Use Committee. A total of 367 New Zealand white rabbits
(6, 12, and 24þ month-old) received subperiosteal injections of growth
factors or vehicle in the medial side of the proximal tibia (see Fig. 1 for dis-
tribution of rabbits). After 1, 3, 5, or 7 days, the rabbits were sacriﬁced and
periosteum containing the injection sites (eight samples per rabbit) was
harvested together with the underlying bone as an intact osteoperiosteal
specimen for histology (to determine cambium cellularity and thickness)13,
or periosteal explants were elevated from the bone at the injection sites
and cultured for 6 weeks (to determine in vitro cartilage forming capacity)6.
Due to limited availability of the older animals, only in vitro cartilage formation
was analyzed in the 24þ month-old rabbits. The rabbit ages were selected
based on previous studies demonstrating signiﬁcantly decreased cambium
cellularity and thickness, and in vitro cartilage forming capacity in periosteum
from rabbits 6e24 months old compared to 2 month-old13.Fig. 2. Schematic drawing of the medial proximal rabbit tibia show-
ing the region bounded by the patellar ligament, growth plate, and
medial collateral ligament that is used for harvesting 3.5 3.5 mm2SUBPERIOSTEAL INJECTIONS
periosteal explants (grid). The four percutaneous injections were
targeted in these regions (circles).
Under general anesthesia (IM Ketamine/Xylazine/Acepromazine at 50/
5.0/0.75 mg/Kg), subperiosteal injections of growth factor or vehicle were
Fig. 3. Cambium cellularity (A), maximum cambium thickness (B) and cambium cell density (C) of periosteum from 12 month-old rabbit tibia
measured 1, 3, 5, or 7 days post-injection of vehicle, TGF-b1 (20, or 200 ng), or TGF-b1 (200 ng) plus IGF-1 (2 mg). Lowercase letters indicate
the results of post-hoc testing using least squares means differences Student’s t-test (P< 0.05). Columns with letters in common are not sta-
tistically different from one another19.
725Osteoarthritis and Cartilage Vol. 17, No. 6performed percutaneously using a Hamilton syringe with a 30-gauge needle.
As illustrated in Fig. 2, a single injection (10 ml) of the same vehicle or growth
factor was made 5 mm proximal to the distal edge of the tibial tuberosity in
each of four approximately 3.5 3.5 mm2 regions on each tibia (correspond-
ing to the area that is normally used for periosteal harvesting in this model)6.
One limb received the growth factor injection and the contralateral limb re-
ceived vehicle, alternating sides to eliminate potential bias (thus eight tissue
samples were generated per rabbit). The 10 ml injections contained recombi-
nant human TGF-b1 (20 or 200 ng) or vehicle (4 mM HCl, 1 mg/ml BSA), re-
combinant human IGF-1 (0.2 or 2.0 mg) or vehicle (10 mM acetic acid, 0.1 %
BSA), or a combination of 200 ng TGF-b1 and 2.0 mg IGF-1 or vehicle (5 mM
acetic acid, 2 mM HCL, 0.1 % BSA). The recombinant human TGF-b1 and
recombinant human IGF-1 were purchased from R&D Systems, Inc. (Minne-
apolis, MN). Prior to initiation of the experiment, dye was injected in rabbit
carcasses in order to establish the injection technique.CAMBIUM CELLULARITY, THICKNESS, AND CELL DENSITYUsing a bone saw, periosteum containing the injection sites was har-
vested together with the underlying bone as an intact osteoperiosteal spec-
imen from the medial proximal tibiae region. The samples were decalciﬁed
using EDTA. After decalciﬁcation, the individual injection sites were sepa-
rated and individually parafﬁn embedded. Each sample was oriented ‘‘on
edge’’ during the embedding process to yield cross-sections of the cambium
layer and underlying bone. Samples were then sectioned at 5 mm thick and
stained with haematoxylin and eosin (H & E). Cambium maximum thickness
(mm), cellularity (cells/mm), and cell density (cells/cm2) were determined by
a blinded technician using a previously published technique13,19 that was
adapted for the KS300 computerized image analysis system (Carl Zeiss Vi-
sion GmbH, Hallbergmoos, Germany). Brieﬂy, three sections were obtained
from each tissue sample and scanned at the injection site using the Zeiss
Table I
Cambium cellularity, thickness and cell density
Days post-injection
Age
(months)
Day 1 Day 3 Day 5 Day 7
Vehicle 20 ng
TGF-b1
200 ng
TGF-b1
Vehicle 20 ng
TGF-b1
200 ng
TGF-b1
Vehicle 20 ng
TGF-b1
200 ng
TGF-b1
Vehicle 20 ng
TGF-b1
200 ng
TGF-b1
Cellularity
(cells/mm)
6 72 51aec 36 39a 129 52beg 87 52aec 163 79fei 145 76deh 86 92aec 175 116gej 128 83ceg 93 65aed 194 131hei 150 149eeh
12 41 45a,b 54 68a,b 22 14a 34 41a,b 62 39a,b 80 57b 64 70a,b 137 100c 184 83c,d 49 46a,b 136 117c 237 130e
Thickness (mM) 6 88 53a,b 60 21a 157 73ceg 98 85aec 132 42bee 162 84deg 113 85aed 200 77eeg 208 88g 108 77aec 279 100h 185 134f,g
12 36 43a,b 28 16a,b 21 12a 24 21a 74 75b,c 43 36a,b 33 26a,b 104 63c,d 115 63c,d 40 27a,b 149 91d 252 120e
Cell Density
(cell/cm2)
6 5 2.6aed 3 1.9a,b 5 2.1aef 5 2.4cef 7 1.7f 5 1.8aef 4 3.3aec 5 2.4aef 8 3.0b 5 2.4aed 5 1.5aee 4 1.8aec
12 7 4.6bee 8 2.0cee 5 3.7aec 5 3.2a,b 8 2.0bee 9 5.4e 8 5.0dee 7 4.7bee 5 1.7d,e 6 4.1aec 5 2.7aec 5 2.0aec
Age
(months)
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Cellularity
(cells/mm)
6 66 31aec 136 113ceg 98 52aef 160 75fei 55 17a,b 230 111j 86 47aee 226 126i,j
12 17 5.9a 25 11a,b 48 37a,b 163 90c,d 46 47a,b 150 74c 50 57a,b 211 154d,e
Thickness (mM) 6 116 78aed 147 92cef 126 78aed 125 52aed 77 45a,b 198 66f,g 103 64aec 206 77g
12 46 73a,b 34 20a,b 47 33a,b 124 106c,d 40 30a,b 145 71d 35 27a,b 260 177e
Cell Density
(cell/cm2)
6 5 1.8aef 5 2.1aef 5 2.6cef 6 2.8eef 5 2.4cef 6 1.6def 5 1.9aef 6 2.4cef
12 4 1.2a 5 3.3a,b 6 3.0aee 8 3.5cee 6 3.7aee 6 1.8aed 5 2.4a,b 5 1.1aec
The data are presented as meansS.D. Lowercase letters indicate the results of post-hoc testing using Student’s test (P< 0.05). Values in each row with letters in common are not sta-
tistically different from one another. The rows from the TGF-b1 experiment (top) can also be compared to the corresponding TGF-b1 & IGF-1 combined experiment (bottom).
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727Osteoarthritis and Cartilage Vol. 17, No. 6AuxioCam MRc at the same magniﬁcation with the periosteal layer line hor-
izontal to the bottom edge of the scan’s frame of reference. Each cambium
layer was outlined by hand. Maximum thickness was determined by compar-
ing thicknesses in the outlined area from top to bottom. For determining cel-
lularity, a custom macro was used to detect, mark and calculate the number
of nuclei in the outlined areas based on color. The computer program deter-
mined the total area occupied by nuclei within the traced cambium layer and
divided that by average nuclear size (determined separately). The total
number of cells within the cambium layer was then divided by the length of
the cambium layer. The result was the average number of cambium cells
per mm. Cell density was determined by dividing the total number of cells
within the cambium layer by the area of the outlined section (cells/cm2).
Values obtain from sections made from the same tissue sample were then
averaged to give overall mean values for cambium maximum thickness,
cellularity and cell density for each tissue sample.IN VITRO CARTILAGE FORMATIONPeriosteum was elevated as four 3.5 3.5 mm2 sections from the me-
dial side of the proximal tibia of 6, 12, or 24þ month-old New Zealand
white rabbits using sharp dissection in the regions of the injection sites
(Fig. 2). All periosteal explants were obtained within 15 min of death toFig. 4. Typical (representative of the means) H & E stained histological sp
days after injection with 200 ng TGF-b1 or 200 ng TGF-b1 plus 2 mcontrol for post-mortem effects on chondrogenic potential. The explants
were then cultured as previously reported6. Brieﬂy, immediately after sur-
gical harvesting, the periosteal explants were placed in Dulbecco’s Modi-
ﬁed Eagle Media (DMEM), 10% FBS with penicillin/streptomycin and
1 mM proline at 4C for no more than 1.5 h prior to transfer to 1% agarose
culture. The medium was supplemented with 10 ng/mL TGF-b1 for the ﬁrst
2 days of culture and 50 mg/mL Vitamin C through the duration of the cul-
ture period. The medium above the gel layer was replaced every second
day. Cultures were maintained for 6 weeks at 37C and 5% CO2 and
95% air. The explants were then weighed, embedded in parafﬁn, sectioned
and stained with Safranin O/fast green. Computerized histomorphometry
was then used by a blinded technician to determine the cartilage yield
(% area) and total cartilage index (% areawet weight¼mg total carti-
lage) in each specimen20,21.STATISTICAL ANALYSISData are expressed as meanS.D. (tables) or S.E.M. (bar graphs). Statis-
tical differences between each treatment group and corresponding vehicle
control were evaluated using one-way Analysis of Variance (ANOVA). Statis-
tical differences between treatment groups were evaluated using the Least
Squares Means Differences Student’s t-Test (P¼ 0.05).ecimens of periosteum on-bone, from 6 and 12 month-old rabbits 7
g IGF-1. The yellow lines and arrows indicate the cambium.
728 G. G. Reinholz et al.: Rejuvenation of PeriosteumResultsCAMBIUM CELLULARITY, THICKNESS AND CELL DENSITYInjection of TGF-b1 with or without IGF-1 increased cam-
bium cellularity and maximum cambium thickness in both
the 6 and 12 month-old rabbits (Fig. 3 and Table I). In the
12 month-old rabbits, cambium cellularity and maximum
cambium thickness values were dependent on the duration
of the treatment (P< 0.0001) and the dose (P 0.0001).
Peak cambium cellularity (252 121 cells/mm, n¼ 13)
and maximum cambium thickness (252 120 mm, n¼ 13),
were observed in the 200 ng TGF-b1 group 7 days post-in-
jection (Fig. 3 and Table I). In the 12 month-old 200 ng TGF-
b1 plus 2.0 mg IGF-1-injected rabbits, the peak cambium
cellularity (211 154 cells/mm, n¼ 11) and maximum cam-
bium thickness (260 177 mm, n¼ 14), also occurred at 7
days post-injection (Fig. 3 and Table I). Cambium cell
density was generally consistent in the 12 month-old rabbits
with the exception being a signiﬁcant increase observed in
the 200 ng TGF-b1 group on day 3 post-injection compared
to vehicle (Fig. 3 and Table I).
In the 6 month-old TGF-b1-injected rabbits, cambium
cellularity and maximum cambium thickness values were
dependent on the duration of the treatment (P< 0.0001)
and the dose (P< 0.02). The peak cambium cellularity
(194 131 cells/mm, n¼ 13) and maximum cambium thick-
ness (279 100 mm, n¼ 13), were found in the 20 ng TGF-
b1 group 7 days post-injection group (Table I). In the 6
month-old 200 ng TGF-b1 plus 2.0 mg IGF-1-injected rab-
bits, cambium cellularity and maximum cambium thickness
values were only dependent on treatment (P< 0.0001) not
duration. In the combined treatment, peak cambium cellu-
larity (230 111 cells/mm, n¼ 15) occurred at 5 days
post-injection while peak maximum cambium thickness
(206 77 mm, n¼ 15) was observed at 7 days post-injec-
tion (Table I). In the 6 month-old rabbits, no signiﬁcant dif-
ferences in cell density compared to vehicle controls were
observed (Table I).
Figure 4 shows examples of typical (representative of the
means) H & E stained histological sections of periosteum
on-bone from the 200 ng TGF-b1 and the 200 ng TGF-b1
plus 2.0 mg IGF-1 combined treatment groups compared
to vehicle controls at 7 days post-injection. In the vehicle
control group, the periosteum in the 6 month-old rabbits is
clearly thicker than in the 12 month-old rabbits. The meanFig. 5. Typical (representative of the means) H & E stained histological spe
7 days after injection with 200 ng TGF-b1 or 200 ng TGF-b1 plus 2maximum cambium thickness of the vehicle-injected limbs
was signiﬁcantly higher in the 6 month-old rabbits
(117 84 mm, n¼ 304 histological samples) compared to
the 12 month-old rabbits (33 30 mm, n¼ 287 histological
samples), P< 0.0001 (data pooled from all time points)
demonstrating the age-related thinning of the periosteum
in the experimental rabbits. Thickening of the periosteum
is apparent in both the 200 ng TGF-b1, and the 2.0 mg
IGF-1 plus 200 ng TGF-b1 groups compared to the vehicle
controls. In addition, increased extracellular matrix is visible
within the cambium of both growth factor treated groups.
Figure 5 illustrates the effect of 200 ng TGF-b1, and the
2.0 mg IGF-1 plus 200 ng TGF-b1 injection in the 12
month-old rabbits over time. In the combined treatment
group, thickening of the cambium was observed by day 3
post-injection, is apparent in both treatment groups by day
5, and increased further by day 7 post-injection. Increased
extracellular matrix in the cambium was noted in both treat-
ment groups by day 5 and increased by day 7 post-
injection.
Subperiosteal injection of IGF-1 (0.2 or 2.0 mg) had no
signiﬁcant effect on cambium layer thickness compared to
vehicle controls in the 6 month-old rabbits at any of the
time points (data not shown). In the 12 month-old rabbits,
a small, but statistically signiﬁcant increase in the maximum
cambium thickness was observed 7 days post-injection in
both the 0.2 mg (44 69 mm, n¼ 16) and 2.0 mg (36 22
mm, n¼ 16) IGF-1 doses compared to vehicle controls
(30  14 mm, n¼ 32), P< 0.05.IN VITRO PERIOSTEAL CARTILAGE FORMATIONInjection of 200 ng TGF-b1 with or without 2.0 mg IGF-1
increased in vitro periosteal cartilage yield, explant wet
weight, and total cartilage index in all age groups after 6
weeks of culture (Figs. 6e8 and Table II). In the 12 month-
old TGF-b1-treated rabbits, cartilage yield, explant wet
weight, and total cartilage index values were dependent on
dose and duration of the treatment (P< 0.0001). Injection
of 200 ng TGF-b1 signiﬁcantly increased in vitro periosteal
cartilage yield and total cartilage index when harvested 5
and 7 days post-injection (Fig. 6 and Table II). Peak cartilage
yield (36 14 %, n¼ 16) and explant wet weight
(27 6.3 mg, n¼ 16) in the 12 month-old rabbits were
observed in the 200 ng TGF-b1 7 day post-injection group,cimens of periosteum on-bone, from 12 month-old rabbits 1, 3, 5, or
mg IGF-1. The yellow lines and arrows indicate the cambium.
Fig. 6. Cartilage Yield (A), explant wet weight (B) and total cartilage index (C) of periosteum from 12-month-old rabbit tibia measured 1, 3, 5, or
7 days post-injection of vehicle, TGF-b1 (20, or 200 ng), or TGF-b1 (200 ng) plus IGF-1 (2 mg). Lowercase letters indicate the results of post-
hoc testing using least squares means differences Student’s t-test (P< 0.05). Columns with letters in common are not statistically different
from one another.
729Osteoarthritis and Cartilage Vol. 17, No. 6resulting in a 12-fold increase in total cartilage index in the
200 ng TGF-b1 (9.7 4.7 mg, n¼ 16) injected rabbits
(P< 0.0001) compared to vehicle controls (0.8 1.0 mg,
n¼ 32). As shown in Fig. 8, a strong correlation between
the mean total cartilage index and cambium cellularity was
observed in the 200 ng TGF-b1-injected rabbits. In the 12
month-old rabbits, wet weight values were dependent on
both duration and treatment, whereas cartilage yield and to-
tal cartilage index were dependent on treatment only
(P< 0.0001). Injection of 200 ng TGF-b1 plus 2.0 mg IGF-1
signiﬁcantly increased cartilage yield when the periosteum
was explanted 1, 5, or 7 days post-injection (Fig. 6 and TableII). The peak cartilage yield (17 17%, n¼ 16) and peak
total cartilage index (3.4 3.9 mg, n¼ 16) values in the com-
bined treatment groups were lower than the 200 ng TGF-b1
in the 12 month-old rabbits. However, when compared to ve-
hicle-injected controls (0.2 0.3 mg, n¼ 16) a comparable
17-fold increase in total cartilage index was observed.
In the 2 year-old rabbits, 200 ng TGF-b1 injections signif-
icantly increased in vitro periosteal cartilage yield at all time
points, and 200 ng TGF-b1 plus 2.0 mg IGF-1 injections in-
creased cartilage yield from periosteum explanted 3, 5,
and 7 days post-injection (Fig. 7 and Table II). In the 2
year-old 200 ng TGF-b1-injected rabbits, explant wet
Fig. 7. Cartilage Yield (A), explant wet weight (B) and total cartilage index (C) of periosteum from 2 year-old rabbit tibia measured 1, 3, 5, or 7
days post-injection of vehicle, TGF-b1 (200 ng), or TGF-b1 (200 ng) plus IGF-1 (2 mg). Lowercase letters indicate the results of post-hoc test-
ing using least squares means differences Student’s t-test (P< 0.05). Columns with letters in common are not statistically different from one
another13.
730 G. G. Reinholz et al.: Rejuvenation of Periosteumweights (P< 0.0001) and total cartilage index (P< 0.004)
were treatment and duration-dependent, whereas cartilage
yield was only treatment dependent (P< 0.0001). In the 2
year-old 200 ng TGF-b1 plus 2.0 mg IGF-1 combined treat-
ment group, cartilage yield (P< 0.0001), explant wet weight
(P< 0.0001) and total cartilage index (P< 0.003) were du-
ration and treatment dependent. In contrast to the 12
month-old rabbits peak cartilage production was observed
in the 200 ng TGF-b1 plus 2.0 mg IGF-1 combined treatment
group. Peak cartilage yield (24 22%, n¼ 16) in the 2 year-
old rabbits was observed in periosteum explanted 3 dayspost-injection and peak total cartilage index (5.1 4.4 mg,
n¼ 16) was found in periosteum explanted 5 day post-
injection.
In the 6 month-old TGF-b1-treated rabbits, cartilage yield
(P< 0.0001), and total cartilage index (P< 0.04) values
were dose and duration-dependent and explant wet weights
(P< 0.0001) were only dose dependent. Injection of 200 ng
TGF-b1 signiﬁcantly increased cartilage yield from perios-
teum explanted 1, 5 and 7 days post-injection in 6 month-
old rabbits. Peak cartilage yield (33 19%, n¼ 16) and
total cartilage index (6.8 1.2, n¼ 16) in the 6 month-old
Fig. 8. Correlation between the total cartilage index and cambium
cellularity from 12-month-old rabbit periosteum injected with vehicle
or TGF-b1 (200 ng) and harvested 1, 3, 5, or 7 days post-injection.
731Osteoarthritis and Cartilage Vol. 17, No. 6rabbits were observed in periosteum explanted 1-day after
injection of 200 ng TGF-b1. In the combined 200 ng TGF-
b1 plus 2.0 mg IGF-1-treated rabbits, total cartilage index
(P< 0.05) and explant wet weights (<0.02) were duration
and treatment dependent. The combined treatment signiﬁ-
cantly increased cartilage yield from periosteum explanted
5 days post-injection (Table II).
Figure 9 contains typical (representative of the means) ex-
amples of safranin O/fast green stained sections of periosteal
explants after in situ vehicle or growth factor injection followed
by six weeks in culture. Themean cartilage yield produced by
periosteal explants after six weeks of culture in the vehicle-in-
jected periosteum was signiﬁcantly higher in the 6 month-old
rabbits (17.6 17.2%, n¼ 319 periosteal explants) com-
pared to the 12 month-old rabbits (7.4 11.1%, n¼ 318 peri-
osteal explants) and the 2 year-old rabbits (1.9 4.6%,
n¼ 188 periosteal explants), P< 0.0001 (data pooled from
all time points) demonstrating an age-related decline in peri-
osteal chondrogenesis in the experimental animals. Figure 9
clearly illustrates the increase in cartilage formation, as de-
tected by safranin O/fast green staining, observed after injec-
tion of 200 ng TGF-b1 alone or in combination with 2.0 mg
IGF-1 followed by six weeks of culture. It is obvious from
these examples that periosteal explant size was also in-
creased. This observation is further illustrated by comparing
the wet weights of the periosteal explants after the culture pe-
riod (Figs. 6 and 7 and Table II). Subperiosteal injection of
IGF-1 (0.2 or 2.0 mg) did not signiﬁcantly increase cartilage
yield, explant wet weights or total cartilage index compared
to vehicle controls at any of the post-injection explant times
in any age group (data not shown). However, injection
200 ng TGF-b1 alone or in combination with 2 mg IGF-1
signiﬁcantly increased wet weight in all age groups.Discussion
Previously, we demonstrated in rabbits that the chondro-
genic potential of periosteum declines with age and that this
decline is closely related to the decrease in the number of
cambium layer cells and cambium thickness observed with
age13. From a technical standpoint, this biological limitation
makes it more difﬁcult to surgically harvest an intact periosteal
graft containing sufﬁcient cambium cells for cartilage tissue
engineering or regeneration. Thus, in order to extend the utilityof periosteum for tissue regeneration to patients past skeletal
maturity, it is necessary to develop methods to rejuvenate
periosteum by increasing the precursor cell pool in the cam-
bium layer to levels similar to those observed during skeletal
growth. In the present study, we demonstrate that it is possible
to reverse these age-related effects on periosteum, at least
temporarily, in rabbits with a single local injection of TGF-b1
alone or in combination with IGF-1.
Based on the samples from the vehicle-injected controls
in this study, the periosteum was thicker and contained
more cambium cells, and produced more cartilage in vitro
in the 6 month-old rabbits compared to the 12 and 24
month-old rabbits, conﬁrming our previous ﬁndings regard-
ing the effects of age on periosteum in the rabbit model13.
Injection of periosteum with IGF-1 alone had little or no
effect on either cambium thickness or in vitro cartilage forma-
tion in any of the ages studied. These results are not entirely
surprising since we previously observed that stimulation of
periosteum in vitro by IGF-1 alone requires continuous expo-
sure to IGF-116. Thus, it is possible that multiple daily injec-
tions of IGF-1 alone would produce better results.
However, this approach was outside the scope of this study.
In contrast, a single subperiosteal injection of 200 ng
TGF-b1 resulted in both thickening of the cambium,
increased cambium cell numbers, and increased in vitro
cartilage production in all age groups examined. The cam-
bium cellularity and thickness ﬁndings are consistent with
the results from multiple TGF-b injections in both newborn
rats17 and rabbits18 reported previously. Whereas, the in
vitro cartilage production results are consistent with our
previous ﬁndings demonstrating that a brief exposure
(30e60 min) of high-dose (50 or 100 ng/mL) TGF-b1 is
sufﬁcient to induce periosteal chondrogenesis in vitro15.
In the present study, subperiosteal injections of TGF-b1
plus IGF-1 produced inconsistent results between the differ-
ent age groups, compared to TGF-b1 alone. An added ben-
eﬁt of IGF-1 on cartilage production was only observed in
the 2 year-old rabbits. Whereas a potential inhibitory effect
of IGF-1 on total cartilage production was observed in the
12 month-old rabbits. However, the fold increases com-
pared to the vehicle controls were similar in the combined
treatment compared to TGF-b1 only. Thus, it is not clear if
these results represent an age associated response differ-
ence or simply variability between the rabbits, sample pro-
curement, or culture conditions. In order to resolve this
issue, the TGF-b1 vs TGF-b1 plus IGF-1 treatments may
need to be compared in the same rabbits.
There are many potential autologous cell sources for
cartilage regeneration including cartilage, bone marrow,
perichondrium, periosteum, adipose, and synovium22,23.
Each cell source has advantages and disadvantages and
the most efﬁcacious cell source for durable cartilage repair
has yet to be determined. Periosteum has been used clini-
cally for biological resurfacing arthroplasty with the majority
of the patients receiving excellent to good results24e33. One
major advantage of the use of a periosteal graft for cartilage
regeneration is the fact that an in vitro cell expansion step is
not required, thus, specialized cell culture facilities are not
needed. As such, this approach should be more globally ac-
cessible than those requiring such facilities. Recent studies
demonstrate that periosteal cells from adult and even
elderly humans retain their proliferative and multilineage ca-
pacity34,35. Speciﬁcally, these isolated human periosteal
cells can form cartilage in vitro in response to TGF-
b134,35. Based on these ﬁndings34,35 and the present study,
it is reasonable to predict that local periosteal injection of
TGF-b1 in humans could be used to increase cambium
Table II
Cartilage Yield, Wet Weight, and Total Cartilage Index
Days post-injection
Age
(Months)
Day 1 Day 3 Day 5 Day 7
Vehicle 20 ng
TGF-b1
200 ng TGF-b1 Vehicle 20 ng
TGF-b1
200 ng
TGF-b1
Vehicle 20 ng
TGF-b1
200 ng
TGF-b1
Vehicle 20 ng
TGF-b1
200 ng
TGF-b1
Cartilage Yield (%) 6 20 17c-f 13 14a-c 33 19g 26 20e-g 17 12b-e 27 21e-g 10 12a,b 13 14a-c 29 21f,g 6 8a 9 11a,b 18 13b-e
12 9 13b,c 14 16c-f 6 9a,b 5 7a,b 9 12b-e 7 9a-c 8 9b,c 6 5a,b 25 19h 15 14d-f 25 13g,h 36 14i
24 0.1 0.3a NA 6 13a-c 0.4 1a NA 6 10a-c 0.3 0.7a NA 5 9a-c 0.9 2a NA 12 10c,d
Wet Weight (mg) 6 11 4.4a,b 12 4.2a,b 19 6.4e-g 14 4.7b-d 18 6.9d-g 15 8.5b-f 10 4.6a 15 8.2b-f 19 6.9g,h 11 6.4a,b 15 5.0b-f 22 7.7g
12 12 6.0c,e 11 3.7b-e 12 5.1c-f 8 3.2a,b,d 10 2.9b-e 14 8.8e-g 8 3.4a,b 20 6.6h,i 21 5.8i 5 2.2a 17 6.2g,h 27 6.3j
24 6 3.8a NA 6 3.8a 6 4.3a NA 8 2.5a,b 9 5.7a,b NA 10 4.7b,c 6 2.8a NA 17 6.4d
Total Cartilage
Index (mg)
6 2.3 0.4a-d 1.5 0.4a-d 6.8 1.2j,k 4.0 0.6e-h 3.1 0.6b-h 4.6 0.94g-j 1.1 0.3a,b 2.2 0.7a-f 5.5 1.3h-k 0.9 0.3a 1.2 0.3a-c 4.3 1.1e-i
12 0.9 1.4a-c 1.7 2.0a-c 0.8 1.1b,c 0.4 0.6a 0.9 1.1a-c 1.2 2.5a-c 0.6 0.7a,b 1.1 1.0a-c 5.7 4.9f 0.8 1.0a,b 4.4 2.8e,f 9.7 4.7g
24 .01 0.02a NA 0.6 1.6a 0.02 0.06a NA 0.6 1.1a 0.02 0.05a NA 0.7 1.4a 0.06 0.2a NA 2.4 2.2b
Age
(Months)
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Vehicle 200 ng TGF-b1&
2 mg IGF-1
Cartilage Yield (%) 6 11 13a-c 16 17b-d 20 20c-f 24 20d-g 9 4a,b 24 4d-g 15 13a-d 9 10a,b
12 2 6a,b 16 18e,f 8 9a-d 8 9a-d 2 3a,b 17 17f,g 0.4 1a 10 10b-f
24 2 2a,b 4 7a,b 8 9b,c 24 22f 6 9a-c 22 17e,f 2 2a,b 16 14d,e
Wet Weight (mg) 6 15 4.6b-f 14 4.3a-d 17 5.8c-f 22 6.2g 12 7.5a-c 30 21h 14 5.7a-d 30 6.8h
12 8 3.9a,b,d 12 4.3c-f 7 2.3a,b 16 8.0f-h 8 2.8a,b 20 6.8h,i 8 4.2a-d 29 19j
24 6 2.9a 9 3.5a-c 8 3.2a,b 13 7.1c 9 3.1a-c 20 6.8d 7 3.8a 30 18e
Total Cartilage
Index (mg)
6 1.8 0.7a-d 3.0 0.7a-g 4.5 5.0f-j 6.3 4.8i-k 2.0 3.1a-e 7.1 7.1k 3.5 3.4c-h 3.7 3.7d-h
12 0.3 1.1a,b 2.0 2.6c,d 0.6 0.8a,b 1.1 1.3a-c 0.2 0.3a 3.4 3.9d,e 0.04 0.2a 2.1 2.3c,d
24 0.08 0.09a 0.4 0.7a 0.7 1.0a 3.7 4.6b,c 0.6 1.0a 5.1 4.4c 0.1 0.1a 4.6 4.8c
The data are presented as meansS.D. Lowercase letters indicate the results of post-hoc testing using Student’s test (P< 0.05). Values in each row with letters in common are not sta-
tistically different from one another. The rows from the TGF-b1 experiment (top) can also be compared to the corresponding TGF-b1 & IGF-1 combined experiment (bottom).
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Fig. 9. Typical (representative of the means) Safranin O/fast green stained histological specimens of cultured periosteum harvested from 6, 12
and 24 month-old rabbits 7 days after injection of vehicle, TGF-b1 (200 ng), or TGF-b1 (200 ng) plus IGF-1 (2 mg).
733Osteoarthritis and Cartilage Vol. 17, No. 6cellularity and periosteal chondrogenesis for cartilage tissue
engineering or regeneration regardless of age.
Results from the present studies clearly demonstrate
that local injection of TGF-b1 alone or in combination
with IGF-1 is a feasible approach to increase cambium
layer thickness and in vitro cartilage production. The cam-
bium cellularity, thickness and cartilage formation values in
the growth factor treated 6e24 month-old rabbits in these
studies are also comparable to our previous observations
in younger rabbits suggesting that periosteum in older rab-
bits can be rejuvenated for tissue engineering13. This ﬁnd-
ing is important because the age-related decline in
periosteal chondrogenesis is considered the primary limita-
tion to the use of periosteum for cartilage tissue regenera-
tion or engineering13,14. The results presented herein also
support the observation made by Kolodny eighty-ﬁve years
ago that ‘‘periosteum of an adult animal plus reactive stim-
ulation are equal to periosteum of a young animal’’, refer-
ring to the bone forming capacity of periosteum36.
However, it is important to note that there are likely to be
differences between the rejuvenated periosteum and peri-
osteum from younger animals that are yet to be deﬁned.
In vivo cartilage regeneration experiments in animal
models are now needed to test the efﬁcacy of periosteal
transplantation to regenerate articular cartilage in adult
animals after in situ TGF-b1 pretreatment. If this simple
approach can be translated to the clinic, the number of pa-
tients who could possibly beneﬁt from the use of perios-
teum for tissue engineering or regeneration of cartilage
would be greatly increased. In addition, it is plausible that
the potential beneﬁts of this rejuvenation approach may
also extend to bone regeneration.Conﬂict of interest
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